Immunohistochemical Analysis of DU-PAN-2, CA19-9, and Lea in Normal Uterine Glands

Immunohistochemical Study of Type-1 Blood Antigen Expressions in Thyroid Tumors: The Significance for Papillary Carcinomas

“…Evidence of frequent expression of CA19 -9 in papillary carcinomas of the thyroid has been provided by previous investigations (14,17). Several immunohistochemical studies, including our own in normal endometrium (15) and endometrial adenocarcinoma (16), have shown the expression of these antigens in normal mucosa as well as in adenocarcinomas of other sites (10 -16). However, normal thyroid tissue was invariably negative for these antigens.…”

“…Indeed, papillary carcinomas of the thyroid occur predominantly in females during their reproductive years (20,21). Our recent studies have indicated that hormonal factors would influence the expressions of DU-PAN-2 and CA19 -9 in normal endometrium but not those in endometrial carcinomas (15,16). We thus examined whether the alteration of the female sex hormone environment would give rise to significant changes of expressions of DU-PAN-2, CA19 -9, Le a , and Le b in thyroid tumors.…”

“…It is interesting that endocervical glands reveal different immunohistochemical profiles. It is assumed that these antigen expressions in the normal endometrium would be closely regulated under the female sex hormone environment (15). Subsequently, we have demonstrated that DU-PAN-2 is expressed more frequently than CA19 -9 in endometrial adenocarcinomas but with no correlation to menopausal status of the patients (16).…”

“…However, several immunohistochemical studies have demonstrated that these two antigens are expressed in adenocarcinomas of several organs and normal counterparts as well as in pancreatic adenocarcinomas (10 -16). We have reported that DU-PAN-2 and CA19 -9 are immunohistochemically expressed distinctly in the late secretory endometrium but with no or occasional expressions in the other cyclic endometrium and postmenopausal atrophic endometrium (15). It is interesting that endocervical glands reveal different immunohistochemical profiles.…”

Clinicopathological Analysis of DU-PAN-2 as a Tumor Marker for Endometrial Adenocarcinoma in Comparison with CA19-9.

“…As a result, we reported that DU-PAN-2 and CA19-9 expressions in the normal endometrium were strongly dependent on hormonal regulation during the menstrual cycle, with the highest expression in the secretory phase [4]. We then demonstrated that DU-PAN-2 expression was more frequent than that of CA19-9 in EMACs of various grades, with no correlation to menopausal status [10].…”